H. Wang

机构：Henan Cancer Hospital

发表论文 1 篇 · 总被引 5 次 · h-index 1

代表论文

• 77P A study to evaluate the safety, tolerability and efficacy of IBI939 in combination with sintilimab in patients with previously untreated locally advanced unresectable or metastatic PD-L1-selected non-small cell lung cancer (NSCLC) (2022 · Immuno-Oncology Technology · 被引 5)